Breast Cancer Research and Treatment

, Volume 116, Issue 2, pp 339–350 | Cite as

A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease

  • Thomas E. Rohan
  • Abdissa Negassa
  • Rowan T. Chlebowski
  • Clementina D. Ceria-Ulep
  • Barbara B. Cochrane
  • Dorothy S. Lane
  • Mindy Ginsberg
  • Sylvia Wassertheil-Smoller
  • David L. Page
Clinical Trial

Abstract

Experimental evidence provides strong support for anti-carcinogenic effects of calcium and vitamin D with respect to breast cancer. Observational epidemiologic data also provide some support for inverse associations with risk. We tested the effect of calcium plus vitamin D supplementation on risk of benign proliferative breast disease, a condition which is associated with increased risk of breast cancer. We used the Women’s Health Initiative randomized controlled trial. The 36,282 participants were randomized either to 500 mg of elemental calcium as calcium carbonate plus 200 IU of vitamin D3 (GlaxoSmithKline) twice daily (n = 18,176) or to placebo (n = 18,106). Regular mammograms and clinical breast exams were performed. We identified women who had had a biopsy for benign breast disease and subjected histologic sections from the biopsies to standardized review. After an average follow-up period of 6.8 years, 915 incident cases of benign proliferative breast disease had been ascertained, with 450 in the intervention group and 465 in the placebo group. Calcium plus vitamin D supplementation was not associated with altered risk of benign proliferative breast disease overall (hazard ratio = 0.99, 95% confidence interval = 0.86–1.13), or by histologic subtype. Risk varied significantly by levels of age at baseline, but not by levels of other variables. Daily use of 1,000 mg of elemental calcium as calcium carbonate plus 400 IU of vitamin D3 for almost 7 years by postmenopausal women did not alter the overall risk of benign proliferative breast disease.

Keywords

Calcium Vitamin D Benign proliferative breast disease 

Notes

Acknowledgments

The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the view of the National Institutes of Health. The authors thank the WHI investigators and staff, and the WHI participants, for their outstanding dedication and commitment.

Funding

The WHI program is funded by the National Heart, Lung and Blood Institute, U.S. Department of Health and Human Services. The present study was supported by National Cancer Institute RO1 CA 077290-07.

References

  1. 1.
    Parkin DM, Fernández LMG (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12(Suppl 1):S70–S80. doi: 10.1111/j.1075-122X.2006.00205.x PubMedCrossRefGoogle Scholar
  2. 2.
    Chen WY, Rosner B, Colditz GA (2007) Moving forward with breast cancer prevention. Cancer 109:2387–2391. doi: 10.1002/cncr.22711 PubMedCrossRefGoogle Scholar
  3. 3.
    Cui Y, Rohan TE (2006) Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev 15:1427–1437. doi: 10.1158/1055-9965.EPI-06-0075 PubMedCrossRefGoogle Scholar
  4. 4.
    Rohan TE, Henson DE, Franco EL, Albores-Saavedra J (2006) Cancer precursors. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York, pp 21–46Google Scholar
  5. 5.
    Wang DY, Fentiman IS (1985) Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 6:5–36. doi: 10.1007/BF01806008 PubMedCrossRefGoogle Scholar
  6. 6.
    Lakhani SR (1999) The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 187:272–278. doi:10.1002/(SICI)1096-9896(199902)187:3<272::AID-PATH265>3.0.CO;2-2PubMedCrossRefGoogle Scholar
  7. 7.
    Santen RJ, Mansel R (2005) Benign breast disorders. N Engl J Med 353:275–285. doi: 10.1056/NEJMra035692 PubMedCrossRefGoogle Scholar
  8. 8.
    Jackson RD, LaCroix AZ, Cauley JA et al (2003) The Women’s Health Initiative calcium–vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol 13(Suppl):S98–S106. doi: 10.1016/S1047-2797(03)00046-2 PubMedCrossRefGoogle Scholar
  9. 9.
    Wactawski-Wende J, Kotchen JM, Anderson GL et al (2006) Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 354:684–696. doi: 10.1056/NEJMoa055222 PubMedCrossRefGoogle Scholar
  10. 10.
    Jackson RD, LaCroix AZ, Gass M et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683. doi: 10.1056/NEJMoa055218 PubMedCrossRefGoogle Scholar
  11. 11.
    Anderson GL, Manson J, Wallace R et al (2003) Implementation of the Women’s Health Initiative study design. Ann Epidemiol 13(Suppl):S5–S17. doi: 10.1016/S1047-2797(03)00043-7 PubMedCrossRefGoogle Scholar
  12. 12.
    Hays J, Hunt JR, Hubbell FA et al (2003) The Women’s Health Initiative recruitment methods and results. Ann Epidemiol 13(Suppl):S18–S77. doi: 10.1016/S1047-2797(03)00042-5 PubMedCrossRefGoogle Scholar
  13. 13.
    Ritenbaugh C, Patterson RE, Chlebowski RT et al (2003) The Women’s Health Initiative dietary modification trial: overview and baseline characteristics of participants. Ann Epidemiol 13(Suppl):S87–S97. doi: 10.1016/S1047-2797(03)00044-9 PubMedCrossRefGoogle Scholar
  14. 14.
    Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR (2003) The Women’s Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 13(Suppl):S78–S86. doi: 10.1016/S1047-2797(03)00045-0 PubMedCrossRefGoogle Scholar
  15. 15.
    Hartmann LC, Sellers TA, Frost MH et al (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353:229–237. doi: 10.1056/NEJMoa044383 PubMedCrossRefGoogle Scholar
  16. 16.
    Page DL, Rogers LW (1992) Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 23:1095–1097. doi: 10.1016/0046-8177(92)90026-Y PubMedCrossRefGoogle Scholar
  17. 17.
    Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF (2003) Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 361:125–129. doi: 10.1016/S0140-6736(03)12230-1 PubMedCrossRefGoogle Scholar
  18. 18.
    Prentice RL, Caan B, Chlebowski RT et al (2006) Low-fat dietary pattern and risk of invasive breast cancer. JAMA 295:629–642. doi: 10.1001/jama.295.6.629 PubMedCrossRefGoogle Scholar
  19. 19.
    Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34:187–220Google Scholar
  20. 20.
    Robins JM, Finkelstein DM (2000) Correcting for non-compliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (PCW) log-rank tests. Biometrics 56:779–781. doi: 10.1111/j.0006-341X.2000.00779.x PubMedCrossRefGoogle Scholar
  21. 21.
    Duchen MR (2000) Mitochondria and calcium: from cell signalling to cell death. J Physiol 529:57–68. doi: 10.1111/j.1469-7793.2000.00057.x PubMedCrossRefGoogle Scholar
  22. 22.
    Kawata H, Lamiakito T, Takayashiki N, Tanaka A (2006) Vitamin D3 suppresses the androgen-stimulated growth of mouse mammary carcinoma SC-3 cells by transcriptional repression of fibroblast growth factor 8. J Cell Physiol 207:793–799. doi: 10.1002/jcp.20618 PubMedCrossRefGoogle Scholar
  23. 23.
    Lips P (2006) Vitamin D physiology. Prog Biophys Mol Biol 92:4–8. doi: 10.1016/j.pbiomolbio.2006.02.016 PubMedCrossRefGoogle Scholar
  24. 24.
    Rohan TE, Jain M, Miller AB (1998) A case-cohort study of diet and risk of benign proliferative epithelial disorders of the breast (Canada). Cancer Causes Control 9:19–27. doi: 10.1023/A:1008841118358 PubMedCrossRefGoogle Scholar
  25. 25.
    Galvan-Portillo M, Torres-Sanchez L, Lopez-Carrillo L (2002) Dietary and reproductive factors associated with benign breast disease in Mexican women. Nutr Cancer 43:133–140. doi: 10.1207/S15327914NC432_3 PubMedCrossRefGoogle Scholar
  26. 26.
    Robien K, Cutler GJ, Lazovich D (2007) Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women’s Health Study. Cancer Causes Control 18:775–782. doi: 10.1007/s10552-007-9020-x PubMedCrossRefGoogle Scholar
  27. 27.
    Lin J, Manson J, Lee I-M, Cook NR, Buring JE, Zhang SM (2007) Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 167:1050–1059. doi: 10.1001/archinte.167.10.1050 PubMedCrossRefGoogle Scholar
  28. 28.
    Chlebowski RT, Johnson KC, Kooperberg C et al Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (in press)Google Scholar
  29. 29.
    Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586–1591PubMedGoogle Scholar
  30. 30.
    Wactawski-Wende J, Anderson GL, O’Sullivan MJ (2006) Calcium plus vitamin D and the risk of colorectal cancer. The authors reply. N Engl J Med 354:2288. doi: 10.1056/NEJMoa055222 CrossRefGoogle Scholar
  31. 31.
    Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18–28PubMedGoogle Scholar
  32. 32.
    Vieth R, Bischoff-Ferrari H, Boucher BJ et al (2007) The urgent need to recommend an intake of vitamin D that is effective. Am J Clin Nutr 85:649–650PubMedGoogle Scholar
  33. 33.
    Rothman KJ (1986) Modern epidemiology. Little Brown, Boston, p 106Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Thomas E. Rohan
    • 1
  • Abdissa Negassa
    • 1
  • Rowan T. Chlebowski
    • 2
  • Clementina D. Ceria-Ulep
    • 3
  • Barbara B. Cochrane
    • 4
  • Dorothy S. Lane
    • 5
  • Mindy Ginsberg
    • 1
  • Sylvia Wassertheil-Smoller
    • 1
  • David L. Page
    • 6
  1. 1.Department of Epidemiology and Population HealthAlbert Einstein College of MedicineBronxUSA
  2. 2.Harbor-UCLA Medical CenterTorranceUSA
  3. 3.School of Nursing and Dental HygieneUniversity of HawaiiHonoluluUSA
  4. 4.School of NursingUniversity of WashingtonSeattleUSA
  5. 5.Department of Preventive Medicine, School of MedicineSUNY at Stony BrookStony BrookUSA
  6. 6.Vanderbilt University Medical SchoolNashvilleUSA

Personalised recommendations